Form 4: Stoke Therapeutics Director Sells Shares Under 10b5-1 Plan

Stoke Therapeutics Director Arthur A. Levin sold 605 shares of common stock for $36.80 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Arthur A. Levin, a Director of Stoke Therapeutics, Inc. (STOK), reported the sale of 605 shares of common stock.
• The transaction occurred on March 13, 2026, at a price of $36.80 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Levin on November 12, 2025.
• Following this transaction, Mr. Levin directly beneficially owns 4,237 shares of common stock.
• Additionally, Mr. Levin indirectly beneficially owns 17,979 shares through the Arthur A. Levin, Ph.D., Trustee, Butler-Levin Revocable Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The sale was pre-planned under a Rule 10b5-1 plan, which mitigates the negative signal often associated with insider selling, indicating a systematic approach to managing personal holdings rather than a reaction to new information.

Positives

• No specific positive financial or operational developments were disclosed in this transaction report, which focuses solely on an insider transaction.

Negatives

• Director Arthur A. Levin disposed of 605 shares of common stock, representing a reduction in his direct holdings.

Risks

• No specific risks were disclosed in this transaction report, which focuses solely on an insider transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions executed under Rule 10b5-1 plans are common practice, allowing company insiders to sell predetermined amounts of stock at pre-scheduled times to manage personal finances without concerns of trading on material non-public information. This particular transaction is a routine disclosure for a director in the biotechnology sector.

Related Party Transactions

• Arthur A. Levin indirectly beneficially owns 17,979 shares through the Butler-Levin Revocable Trust, where he serves as a Trustee.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors as this is a routine insider transaction report under a pre-arranged plan.

Key Dates

Recommendation

A director's sale of a relatively small number of shares under a pre-established 10b5-1 trading plan is generally considered a neutral event. It typically reflects personal financial planning rather than a change in the insider's view of the company's prospects. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' position based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Equity Transaction, Biotechnology